In the company’s recent news,
The company announced that Novartis Pharma AG and Nordic Bioscience have completed recruitment of patients for a multi-center, phase III study of an oral formulation of salmon calcitonin using Emishpere’s Elgin Technology, developed to treat osteoarthritis of the knee.
Osteoarthritis affects roughly 21 million people in the United States each year. This inflammatory affliction accounts for 25 percent of visits to primary care physicians, and represents half of all non-steroidal anti-inflammatory drug prescriptions. Osteoarthritis can be extremely painful, whether sitting or standing, as the cartilage between joints wears away. Approximately 80 percent of Americans are expected to suffer from this affliction by the time they are 65 years of age.
“The problems associated with osteoarthritis will escalate as the population ages,” said Michael V. Novinski, president and CEO of Emisphere stated in the press release. “This phase III study aims at demonstrating that oral salmon calcitonin, in combination with our Eligen drug delivery technology, may contribute to solving this problem, and also shows that Emisphere is a valuable partner in drug development.”
This study, to be conducted mainly in Europe, will involve more than 1,100 patients between 51 and 80 years old with a medical history and symptoms of knee osteoarthritis. The company expects the study to be completed in the second half of 2010.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
